Chronic liver diseases are a major public health concern and confer a high economic burden. Non-alcoholic fatty liver disease (NAFLD), hepatocellular carcinoma (HCC) and biliary diseases rank at the top when it comes to the need for novel biomarkers of diagnosis, progression and prognosis.
The purpose of this course is to highlight what makes a good noninvasive biomarker, explain the application of biomarkers in clinical practice and introduce microRNAs (miRNAs/miRs) and extracellular vesicles (EVs) as novel noninvasive biomarkers in the setting of liver diseases.
To become familiar with:
- The aetiology and epidemiology of NAFLD, HCC and biliary diseases
- The need for novel biomarkers of liver disease
- Characteristics of a good clinical biomarker
- The spectrum of currently available noninvasive biomarkers, including their accuracy and limitations
- The definition and function of miRNAs and EVs
- The role of miRNAs and EVs in NAFLD, HCC and biliary diseases
- miRNAs and EVs as novel biomarkers of liver disease
This course is suitable for hepatologists in training and scientists working in translational biomedicine, and is also appropriate for other physicians, nurses, biotechnicians, pharmacists, scientists in other disciplines and medical students who have an interest in hepatology and biomarker development.